Researchers at the University of Nebraska Medical Center published a study April 20, 2026 in Molecular Psychiatry that analyzed 6.14 million U.S. birth records and found that commonly prescribed medications that inhibit cholesterol synthesis were associated with a 47% higher risk of autism diagnosis. The medications include widely used antidepressants, beta-blockers, and statins. When four or more of these medications were prescribed simultaneously during pregnancy, the risk climbed to 2.33 times baseline.

The findings don't mean these medications are unsafe for adults or that pregnant people should stop taking them. They identify a specific biological mechanism that warrants discussion between patients and doctors about individual risk and possible alternatives.

What the Study Found

The research team analyzed birth records from the Epic Cosmos database spanning 2014 to 2023, with follow-up through December 2025. They examined 14 medications known to inhibit sterol biosynthesis, the pathway responsible for cholesterol production in the body.

The medications studied were aripiprazole, atorvastatin, bupropion, buspirone, fluoxetine, haloperidol, metoprolol, nebivolol, pravastatin, propranolol, rosuvastatin, sertraline, simvastatin, and trazodone.

Mothers prescribed at least one of these medications during pregnancy had a 1.47-fold higher risk of having a child later diagnosed with autism spectrum disorder. Risk increased with each additional medication, climbing 1.33 times for every sterol-inhibiting drug co-prescribed.

The pattern held across different medication classes. Whether the drug was an antidepressant, a beta-blocker, or a statin, the shared mechanism of cholesterol pathway disruption showed a consistent association with autism diagnosis.

Why Cholesterol Matters for Fetal Brain Development

Cholesterol is essential for fetal development. The brain is the most cholesterol-rich organ in the body, and the fetal brain begins producing its own sterols around 19 to 20 weeks of gestation.

Genetic disruptions in the cholesterol synthesis pathway cause severe developmental syndromes. Smith-Lemli-Opitz syndrome, caused by a mutation in the final step of cholesterol production, results in up to 75% of affected children meeting criteria for autism spectrum disorder.

"Our findings don't suggest that these medications are unsafe for adults," said senior author Karoly Mirnics, MD, Ph.D., dean and director of the UNMC Munroe-Meyer Institute. "But they raise important questions about their use during pregnancy, a period when even small biochemical disruptions may have outsized effects on fetal brain development."

The study doesn't prove that these medications cause autism. It identifies an association that requires further investigation and raises clinical questions about prescribing patterns during pregnancy.

What This Means for Pregnant People Currently on These Medications

Don't stop taking prescribed medications without talking to your doctor. Many of these medications are prescribed for conditions that themselves carry risks during pregnancy. Untreated depression, uncontrolled high blood pressure, and other conditions can affect both maternal and fetal health.

The study identifies a biological mechanism worth discussing with your healthcare provider. That discussion should include your individual risk factors, the severity of the condition being treated, and whether alternative medications that don't inhibit cholesterol synthesis are appropriate for your situation.

Some pregnant people have limited options. Discontinuing a medication that stabilizes a serious mental health condition or controls a cardiovascular issue may pose greater risks than continuing it.

The researchers recommend that healthcare providers discuss safer alternatives when discontinuing treatment isn't possible and avoid prescribing multiple sterol-inhibiting medications simultaneously whenever feasible.

What This Means for Families Raising Children with Autism

This study adds to the growing understanding of autism's biological underpinnings. Identifying cholesterol metabolism as a potential pathway opens new directions for research into both causation and intervention.

Autism is a spectrum condition with multiple contributing factors. No single environmental exposure or genetic variant accounts for all cases. This study identifies one piece of a complex picture.

For families who took these medications during pregnancy and have children with autism, the findings don't establish direct causation. They describe population-level risk patterns that can't predict individual outcomes.

The research also highlights genetic vulnerabilities. Some people have pre-existing variations in genes related to cholesterol metabolism, which may make them particularly sensitive to medications that further disrupt this pathway. Future screening could identify these individuals before pregnancy.

Where Research Goes Next

The study's authors call for increased provider education about medication-associated sterol disruption during pregnancy and for identifying patients with genetic vulnerabilities in sterol metabolism.

Future research will need to examine whether the timing of medication exposure during pregnancy affects risk, whether certain medications within each class show stronger associations than others, and whether nutritional or supplemental interventions could mitigate risk when discontinuing medication isn't safe.

The dataset used in this study represents nearly one-third of all U.S. births during the study period. That scale provides statistical power that smaller studies lack, but it also raises questions about subpopulations that may have different risk profiles.

What Families Can Do Now

If you're pregnant or planning pregnancy and currently take one of the medications listed in the study, schedule a conversation with your prescribing doctor. Bring a list of all medications you're taking, including over-the-counter drugs and supplements.

Ask whether alternative medications that don't affect cholesterol synthesis are appropriate for your condition. If no alternatives exist or if switching carries its own risks, ask what monitoring or precautions make sense given current evidence.

Don't assume that because a medication is commonly prescribed, your doctor is aware of recent research on prenatal exposure. The study was published in April 2026, and clinical guidelines take time to incorporate new evidence.

For families raising children with autism, this research doesn't change your child's diagnosis or care plan. It adds to the scientific understanding of potential contributing factors and may inform future prevention strategies for others.

The full text of the study is available in Molecular Psychiatry.